Henan Lingrui Pharmaceutial Co., Ltd. Class A

Henan Lingrui Pharmaceutial Co., Ltd. Class A

SSSE:600285
24.00
CNY
+0.57
(+2.43%)
1.47EPS
12.98P/E
10.76BMarket Cap
Apr 28Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.3
1.52
2.06
2.5
3.15
3.48
3.75
4.1
4.84
5.39
5.9
6.24
6.8
6.98
Basic EPS, GAAP
0.2
0.14
0.25
0.6
0.37
0.41
0.51
0.57
0.65
0.84
1.01
1.29
1.34
1.46
Free Cash Flow per Basic Share
-0.08
0.04
0.24
-0.27
-0.26
0.65
0.68
0.67
1.38
1.45
1.41
1.36
0.88
- -
Dividend per Share
0.07
0.13
0.1
0.17
0.17
0.18
0.17
0.32
0.4
0.52
0.61
0.8
0.9
1.1
Book Value per Share
1.81
2.88
3.22
3.52
3.67
3.65
3.89
4.07
4.01
4.5
4.92
5.42
6
6.1
Tangible Book Value per Share
1.45
2.55
2.87
3.21
3.13
3.12
3.36
3.57
3.51
4.07
4.52
5.05
4.54
4.63
Basic Weighted Avg Shares
527
544
528
576
587
590
575
568
556
557
561
561
567
566
Sales/Revenue/Turnover
687
826
1,085
1,439
1,849
2,053
2,157
2,332
2,694
3,002
3,311
3,501
3,853
3,952
Operating Margin (%)
9.51
8.19
12.68
12.29
14.71
15.14
16.47
14.36
15
14.31
18.41
21.64
21.76
23.03
Depreciation Expense
29
30
37
43
50
68
68
68
73
76
78
74
99
- -
Net Income, GAAP
105
76
132
346
217
243
294
325
362
465
568
723
760
827
Effective Tax Rate (%)
14.01
11.15
13.76
15
14.71
13.27
14.11
10.93
12.3
10.01
13.01
12.69
13.31
13.42
Profit Margin (%)
15.34
9.22
12.16
24.02
11.75
11.85
13.65
13.96
13.42
15.5
17.16
20.64
19.71
20.94
Working Capital
266
62
76
806
608
652
741
849
694
796
699
584
164
593
LT Debt
25
- -
40
20
- -
- -
- -
8
8
6
7
7
4
3
Total Equity
985
1,561
1,745
2,112
2,204
2,154
2,220
2,322
2,287
2,558
2,799
3,080
3,436
3,498
Return on Invested Capital (%)
8.76
4.22
6.06
14.84
9.15
10.32
12.21
13.53
15.56
17.81
19.76
22.76
21.8
21.69
Return on Capital (%)
9.58
5.3
6.69
15.61
9.13
10.53
12.92
13.92
15.16
18.34
20.26
23.78
21.85
22.34
Return on Common Equity (%)
12.8
6.07
8.07
18.14
10.19
11.27
13.53
14.39
15.75
19.27
21.27
24.65
23.47
25.36

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
276
363
319
LT Borrowings
- -
- -
- -
LT Finance Leases
5
4
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
567
567
567
Market Capitalization
12,675
10,991
10,764

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
2,566
2,838
3,192
Cash, Cash Equivalents & STI
744
874
1,023
Accounts Receivable, Net
551
607
668
Inventories
393
359
363
Total Current Liabilities
2,191
2,408
2,599
Payables & Accruals
- -
- -
- -
ST Debt
276
363
319
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.22%
8.27%
11.55%
Free Cash Flow
-51.02%
13.5%
-34.66%
Net Income, GAAP
26.27%
18.83%
5.11%
Sales/Revenue/Turnover
13.84%
10.61%
10.07%
Total Cash Common Dividend
29.75%
23.52%
13.28%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
909
997
853
742
3,501
2025
1,021
1,078
- -
812
3,853
2026
1,126
1,022
992
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.34
0.39
0.28
0.26
1.29
2025
0.38
0.45
- -
0.19
1.34
2026
0.44
0.44
0.4
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.79
- -
- -
0.8
2025
- -
0.9
- -
- -
0.9
2026
- -
1.1
- -
- -
- -

Company Description

CEO
Wei Xiong
Full Time Employees
2,789
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No.666 Jiangjun Road Xinyang HN China 465550
IPO Date
Oct 18, 2000
Business
Henan Lingrui Pharmaceutical Co., Ltd., founded in June 1992 and headquartered in Henan, China, is a national high-tech pharmaceutical enterprise specializing in the research, development, production, and sales of pharmaceuticals and medical devices. The company manufactures over 100 products across more than 10 dosage forms including adhesive plasters, tablets, capsules, granules, ointments, tinctures, and sprays, covering therapeutic areas such as orthopedics, cardiovascular and cerebrovascular diseases, pulmonology, dermatology, endocrinology, and anesthesiology. Key products include Tongluoqutong Plasters, Peiyuantongnao Capsules, Danlutongdu Tablets, Shenqi Hypoglycemic Capsules, and salmon calcitonin nasal spray. Henan Lingrui also operates through several subsidiaries across Beijing, Changzhou, Zhengzhou, and Xinyang, primarily serving the Chinese domestic market with a focus on markets in Henan Province and Beijing. The company maintains GMP certification for all its dosage forms, products, and manufacturing workshops, ensuring compliance with national and international quality standards. Recently, Henan Lingrui Pharmaceutical has been emphasizing innovative pharmaceutical commercialization and export growth, reversing previous declines in overseas authorization trade, signaling a strategic expansion toward international markets. In the last 1-2 years, Henan Lingrui has been actively developing new product offerings and furthering R&D capabilities, while maintaining its strong presence in traditional Chinese medicine treatments for orthopedic and cardiovascular diseases. It has strategically diversified into health care products and maintained significant innovation with products that possess exclusive intellectual property rights. The firm continues to solidify its status as a leading enterprise in China's pharmaceutical sector, ranking among the top traditional Chinese medicine enterprises with multiple awards at municipal, provincial, and national levels. Its latest financial trends indicate a positive short-term market outlook supported by solid fundamentals and increasing liquidity. Henan Lingrui's business segments include pharmaceutical and health care, focusing on plasters, oral medicines, and ointments, with ancillary businesses in hospitality and catering. The company is publicly listed on the Shanghai Stock Exchange under ticker 600285.SS and reported nearly 3.7 billion CNY in revenue (TTM). Its strategic goals include leveraging unique proprietary formulations and expanding its footprint in both domestic and selected international markets. This comprehensive approach across R&D, manufacturing, and sales, combined with recent operational expansions and export growth, positions Henan Lingrui Pharmaceutical as a significant player in the pharmaceutical industry in China and increasingly in global markets.